SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT00371826
- Locations
- 🇦🇺
Westmead Hospital, NSW, Australia
🇦🇺Sir Charles Gairdner Hospital, WA, Australia
🇦🇺Monash Medical Centre, Sale, Australia
Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee
- Conditions
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT00371670
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇩🇪Novartis, Nuernberg, Germany
Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 128
- Registration Number
- NCT00369278
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 901
- Registration Number
- NCT00368277
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT00367471
- Locations
- 🇺🇸
Novartis Investigative Site, Greensboro, North Carolina, United States
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT00363051
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Scott & White Memorial Hospital, Temple, Texas, United States
A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT00351507
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 370
- Registration Number
- NCT00351884
- Locations
- 🇩🇪
Novartis Investigative Site, Investigative Centers, Germany
🇺🇸Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00351377
- Locations
- 🇩🇪
Novartis Investigational Site, Various cities, Germany
EXTEND (Eltrombopag Extended Dosing Study)
- Conditions
- Interventions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 302
- Registration Number
- NCT00351468
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
🇹🇳Novartis investigative Site, Sfax, Tunisia